These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30654737)

  • 21. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
    Khatib AM; Nip J; Fallavollita L; Lehmann M; Jensen G; Brodt P
    Int J Cancer; 2001 Feb; 91(3):300-8. PubMed ID: 11169951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
    Jin T; Bokarewa M; Zhu Y; Tarkowski A
    Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of urokinase-type plasminogen activator and its receptor during ovarian follicular development.
    Li M; Karakji EG; Xing R; Fryer JN; Carnegie JA; Rabbani SA; Tsang BK
    Endocrinology; 1997 Jul; 138(7):2790-9. PubMed ID: 9202219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1).
    Suelves M; Vidal B; Ruiz V; Baeza-Raja B; Diaz-Ramos A; Cuartas I; Lluis F; Parra M; Jardi M; Lopez-Alemany R; Serrano AL; Munoz-Canoves P
    Front Biosci; 2005 Sep; 10():2978-85. PubMed ID: 15970552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
    Deng G; Curriden SA; Wang S; Rosenberg S; Loskutoff DJ
    J Cell Biol; 1996 Sep; 134(6):1563-71. PubMed ID: 8830783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1.
    Mimuro J; Kaneko M; Murakami T; Matsuda M; Sakata Y
    Biochim Biophys Acta; 1992 Dec; 1160(3):325-34. PubMed ID: 1477106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
    Lijnen HR; Van Hoef B; Lupu F; Moons L; Carmeliet P; Collen D
    Arterioscler Thromb Vasc Biol; 1998 Jul; 18(7):1035-45. PubMed ID: 9672063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
    Baker EA; Bergin FG; Leaper DJ
    Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
    Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
    EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.
    Rakic JM; Lambert V; Munaut C; Bajou K; Peyrollier K; Alvarez-Gonzalez ML; Carmeliet P; Foidart JM; Noël A
    Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1732-9. PubMed ID: 12657615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
    Lijnen HR; Silence J; Lemmens G; Frederix L; Collen D
    Thromb Haemost; 1998 Jun; 79(6):1171-6. PubMed ID: 9657444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
    Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
    Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
    Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
    Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
    Nagai N; De Mol M; Lijnen HR; Carmeliet P; Collen D
    Circulation; 1999 May; 99(18):2440-4. PubMed ID: 10318667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.